Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

22.53
-0.7050-3.03%
Volume:261.89K
Turnover:5.95M
Market Cap:1.33B
PE:1.95
High:23.09
Open:22.96
Low:22.32
Close:23.24
52wk High:49.95
52wk Low:6.50
Shares:59.16M
Float Shares:37.23M
Volume Ratio:0.73
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):11.53
EPS(LYR):-70.5015
ROE:-125.43%
ROA:-21.37%
PB:-6.66
PE(LYR):-0.32

Loading ...

Rpt-Vor Biopharma Q4 Net Income USD 1,722.8 Million VS. Ibes Estimate USD -28.9 Million

THOMSON REUTERS
·
Mar 30

Vor Bio Doses First Patient in Global Phase 3 Upstream Sjd Registrational Trial of Telitacicept in Primary SjÖGren’s Disease

THOMSON REUTERS
·
Mar 30

Jefferies Initiates Vor Biopharma at Buy With $50 Price Target

MT Newswires Live
·
Mar 30

Vor Biopharma Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $50

THOMSON REUTERS
·
Mar 30

Vor Bio initiated with a Buy at Jefferies

TIPRANKS
·
Mar 30

Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating

TIPRANKS
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

Vor Biopharma Shares Rise 1.5% After $75 Million Private Placement

THOMSON REUTERS
·
Mar 27

Vor Biopharma Announces $75 Million Private Placement

MT Newswires Live
·
Mar 27

Vor Biopharma Shares Climb 6.4% Premarket After $75 Million Private Placement

THOMSON REUTERS
·
Mar 27

Vor Bio sells 5,338,078 shares in private placement; gross proceeds rise to $75 million

Reuters
·
Mar 27

BRIEF-Vor Bio Announces $75 Million Private Placement With Tcgx

Reuters
·
Mar 27

Vor Biopharma Inc - Bio to Use Proceeds to Advance Telitacicept Clinical Development

THOMSON REUTERS
·
Mar 27

BRIEF-Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Mar 24

Vor Bio reports inducement grants of 215,700 stock options and 46,235 RSUs under Nasdaq Rule 5635(c)(4)

Reuters
·
Mar 24

Vor Biopharma Inc expected to post a loss of $1.64 a share - Earnings Preview

Reuters
·
Mar 16